Notice of Proposed Sale · 144
10x Genomics, Inc.
TXGNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- 10X GENOMICS, INC.
- Issuer CIK
- 0001770787
- SEC file number
- 001-39035
- Phone
- (925) 401-7300
- Person for whose account securities are to be sold
- SARAH A POLONIUS-TEICHMANN
- Relationships to issuer
- Director
- Street
- 6230 Stoneridge Mall Road
- City
- Pleasanton
- State / country code
- CA
- Postal code
- 94588
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 2,273 | 129,901.95 | 120,212,296 | 08/14/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 11/21/2025 | Restricted Stock | ISSUER | 1,155 | N | 11/21/2025 | Not Applicable |
| Common | 02/21/2026 | Restricted Stock | ISSUER | 1,118 | N | 02/21/2026 | Not Applicable |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| SARAH A POLONIUS-TEICHMANN | Common | 08/13/2026 | 5,278 | 302,376.62 |
Seller — prior-sale row 1, entry 1
- Name
- SARAH A POLONIUS-TEICHMANN
- Street
- 6230 Stoneridge Mall Road
- City
- Pleasanton
- State / country code
- CA
- Postal code
- 94588
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 08/14/2026
- Signed
- /s/ Sarah Amalia Polonius-Teichmann
- Plan adoption dates
- 05/14/2026
Company context
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.